(Q51412875)

5 April 2018

title

Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. (English)

1 reference

5 April 2018

1 reference

J Dreiher

1

1 reference

5 April 2018

F S Kresch

series ordinal

2

1 reference

5 April 2018

D Comaneshter

series ordinal

3

1 reference

5 April 2018

A D Cohen

series ordinal

4

1 reference

5 April 2018

publication date

16 September 2011

1 reference

5 April 2018

Journal of the European Academy of Dermatology and Venereology

published in

1 reference

5 April 2018

volume

26

1 reference

5 April 2018

issue

9

1 reference

5 April 2018

page(s)

1127-1132

1 reference

5 April 2018

The immunologic basis for the treatment of psoriasis with new biologic agents

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Clinical practice. Herpes zoster

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Herpes zoster in the age of focused immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

What does epidemiology tell us about risk factors for herpes zoster?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04230.X

10.1111/J.1468-3083.2011.04230.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018